TGFbetaReceptorII抗体;TGFbetaReceptorII Antibody—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     Western blot analysis of TGF beta Receptor II expression in A549 cell lysate.    

  
  

The TGF-beta receptor type II (TGFβRII) antibody targets a key component of the transforming growth factor-beta (TGF-β) signaling pathway, which regulates diverse cellular processes, including proliferation, differentiation, apoptosis, and immune responses. TGFβRII is a transmembrane serine/threonine kinase receptor that binds TGF-β ligands (e.g., TGF-β1. TGF-β2. TGF-β3) and recruits TGFβRI to form a heteromeric complex, initiating downstream Smad-dependent and non-Smad signaling. Dysregulation of TGFβRII is linked to pathologies such as cancer, fibrosis, and autoimmune diseases.

TGFβRII antibodies are widely used in research to study receptor expression, localization, and signaling dynamics. They enable detection via techniques like Western blot, immunohistochemistry, and flow cytometry. Some antibodies block receptor-ligand interactions, serving as tools to inhibit TGF-β signaling in experimental models. Clinically, TGFβRII-targeting antibodies are explored for therapeutic applications, particularly in cancers where TGF-β promotes metastasis or immunosuppression, and in fibrotic disorders to counteract excessive tissue remodeling. Variants include monoclonal antibodies for specificity and recombinant antibodies for reduced immunogenicity. Their development faces challenges related to balancing pathway inhibition with off-target effects, given TGF-β's dual tumor-suppressive and pro-oncogenic roles.